These are relatively new drugs whose long-term safety remains incompletely understood.
In a country where the hunger for rapid transformation had outpaced the guardrails of medical oversight, Brazil's health regulator Anvisa moved on June 23rd, 2025, to restore a measure of accountability to the dispensing of GLP-1 weight-loss medications. The new rule — requiring pharmacies to retain prescriptions for drugs like Ozempic and Wegovy and log all transactions in a national system — responds to a pattern of harm that Brazilian data made impossible to ignore. It is, at its core, a reminder that even medicines born of genuine therapeutic promise can become instruments of risk when desire outruns supervision.
- Brazil's pharmacovigilance system flagged a disproportionately high rate of adverse events from unsupervised GLP-1 use, signaling a public health problem that had been quietly building.
- Weight-loss pens were being sold without prescriptions despite existing legal requirements, exposing people to serious risk while draining supplies from diabetic patients who depended on them.
- Starting June 23rd, pharmacies must now keep a copy of every GLP-1 prescription on file and log each transaction in a national registry — mirroring controls already applied to antibiotics.
- Doctors retain the right to prescribe off-label, but the new duplicate-prescription system creates visible accountability where casual, undocumented dispensing once flourished.
- Major medical societies welcomed the measure, though the real test lies ahead: whether pharmacies comply consistently and whether the paper trail actually changes behavior on the ground.
On June 23rd, 2025, Brazil's health regulator Anvisa put into force a new rule reshaping how weight-loss medications move through the country's pharmacies. Any pharmacy dispensing GLP-1 agonist drugs — including Ozempic, Mounjaro, and Wegovy, across six active compounds — must now retain a copy of the patient's prescription. Prescriptions are issued in duplicate, remain valid for up to 90 days, and must be logged in Brazil's National Controlled Products Management System to prevent reuse or diversion. The framework mirrors existing controls on antibiotics.
The measure was driven by a troubling signal in Anvisa's pharmacovigilance data: Brazil was recording a markedly higher rate of adverse events from off-label use of these medications than global figures suggested. Off-label prescribing is legal when a physician judges the benefits justified and informs the patient — but what the data revealed was something different: widespread unsupervised use, often for cosmetic weight loss, without proper evaluation or follow-up.
Major Brazilian medical societies had long called for tighter oversight, pointing out that these drugs were being sold without prescriptions despite legal requirements. Beyond the safety concern, the surge in demand was depleting supplies for type 2 diabetic patients for whom the medications were originally developed. Anvisa's acting director-president Rômison Rodrigues Mota underscored that these are still relatively new drugs whose long-term safety profiles are not fully understood, and that marketing them for aesthetic purposes without medical supervision multiplies the risk of harm.
The regulation does not curtail physicians' authority to prescribe off-label — it adds friction and visibility. The prescription must be written, duplicated, filed, and logged. Whether pharmacies comply consistently, and whether that accountability genuinely alters prescribing culture, remains the open question now that the rule is in effect.
Starting Monday, June 23rd, Brazil's health regulator Anvisa implemented a new rule that will reshape how weight-loss medications flow through the country's pharmacies. From that date forward, every pharmacy dispensing GLP-1 agonist drugs—the injectable medications known colloquially as weight-loss pens, including Ozempic, Mounjaro, and Wegovy—must retain a copy of the patient's prescription on file. The rule applies to six active compounds: semaglutide, liraglutide, dulaglutida, exenatida, tirzepatida, and lixisenatida.
The decision, announced by Anvisa in April, represents a significant tightening of oversight. Prescriptions will now be issued in duplicate: one copy goes to the patient, the other stays with the pharmacy. Prescriptions remain valid for up to 90 days from the date a doctor writes them. Pharmacies must log all transactions in Brazil's National Controlled Products Management System to prevent prescriptions from being reused or diverted. The mechanism mirrors existing controls on antibiotics and other regulated medications—a familiar framework applied to a new category of drugs that have become central to contemporary medicine and, increasingly, to cultural anxieties about weight and appearance.
Anvisa's stated rationale centers on a troubling pattern of adverse events. The agency's pharmacovigilance system, VigiMed, flagged a notably higher rate of harmful reactions tied to off-label use of these medications in Brazil compared to global reporting. Off-label use—prescribing a drug for purposes not listed on its approved label—is legal when a doctor judges the benefits outweigh the risks and informs the patient accordingly. But the data suggested something else was happening: widespread unsupervised use, often for purely cosmetic weight loss, without proper medical evaluation or ongoing monitoring. The new rule aims to create a paper trail that makes such indiscriminate dispensing harder to sustain.
The measure had been anticipated and welcomed by major medical societies. The Brazilian Society of Endocrinology and Metabolism, the Brazilian Society of Diabetes, and the Brazilian Association for the Study of Obesity and Metabolic Syndrome jointly issued a statement emphasizing the problem the regulation now addresses. These medications, they noted, were being sold without prescriptions despite legal requirements—a gap in enforcement that enabled self-medication and exposed people to unnecessary risk. The societies worried, too, about equity: as demand for weight-loss drugs surged, supplies dwindled for patients who genuinely needed them, particularly those with type 2 diabetes for whom these medications were originally developed and approved.
Rômison Rodrigues Mota, Anvisa's acting director-president, articulated the deeper concern when the board voted in April. These are relatively new drugs whose long-term safety profiles remain incompletely understood. Marketing them primarily for aesthetic purposes, accompanied by testimonials of rapid weight loss and without medical supervision, creates real danger. The absence of proper evaluation, prescription, and follow-up by qualified professionals—especially when use deviates from approved indications—multiplies the risk of harm. Mota emphasized that monitoring and vigilance are not bureaucratic luxuries but essential safeguards.
The regulation does not strip doctors of their authority to prescribe off-label. A physician can still recommend these medications for purposes beyond what the label specifies, provided the decision is made responsibly and the patient is fully informed. What changes is the friction: the prescription must be written in duplicate, handed over to a pharmacist who files it, and logged in a national system. These steps are designed not to prevent prescribing but to make it visible, to create accountability, and to slow the momentum of casual, unsupervised use that had been accelerating in Brazil's pharmacies. The rule took effect 60 days after publication in the official gazette, giving the system time to prepare. Now the question is whether the infrastructure will hold, whether pharmacies will comply consistently, and whether the visibility this creates will actually change prescribing and dispensing behavior on the ground.
Citações Notáveis
The absence of proper evaluation, prescription, and follow-up by qualified professionals multiplies the risk of harm.— Rômison Rodrigues Mota, Anvisa acting director-president
The sale of GLP-1 agonists without medical prescription, despite being irregular, is frequent. This gap in the law facilitates indiscriminate access and self-medication, exposing individuals to unnecessary risks.— Brazilian Society of Endocrinology and Metabolism, Brazilian Society of Diabetes, and Brazilian Association for the Study of Obesity and Metabolic Syndrome (joint statement)
A Conversa do Hearth Outra perspectiva sobre a história
Why did Brazil's regulator feel compelled to act now, rather than waiting to see how these drugs played out in the real world?
Because the real world was already sending signals. Their pharmacovigilance system was picking up more adverse events from off-label use here than anywhere else globally. That's not a small thing—it suggested something was broken in how these drugs were being distributed and used.
But these medications are legal. Doctors can prescribe them. Why does the government need to get between a doctor and a patient?
The issue isn't the doctor-patient relationship. It's that the drugs were being sold without prescriptions at all, or with prescriptions that could be reused endlessly. The regulation doesn't stop doctors from prescribing off-label. It just makes it harder to hand a prescription to a friend, or to refill it five times, or to buy it without ever seeing a doctor.
So this is really about preventing black-market use and self-medication?
Partly. But it's also about scarcity. Type 2 diabetics—the people these drugs were designed for—were having trouble getting them because demand from people seeking weight loss had exploded. The medical societies were saying: we need to protect access for the people who actually need this for their disease.
Does the regulation actually prevent off-label prescribing?
No. A doctor can still write a prescription for cosmetic weight loss if they think it's justified and they've informed the patient. What it does is create a record, a pause, a moment where the pharmacist has to file it instead of just handing it back. That friction matters.
What happens if a pharmacy doesn't comply?
That's the real question. The rule is in place, but enforcement is always the harder part. If pharmacies don't actually retain prescriptions or don't log them in the national system, the whole thing falls apart. The regulation is only as strong as the willingness to enforce it.
And the long-term safety question—does this rule address that?
Not directly. But by creating oversight and requiring medical supervision, it at least ensures that if something goes wrong, there's a record and a doctor involved. You can't monitor what you can't see.